A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19

NCT05305547 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2093

Enrollment

INDUSTRY

Sponsor class

Conditions

SARS-CoV-2 Infection

Interventions

DRUG: S-217622
DRUG: Placebo

Sponsor

Shionogi

Collaborators

[object Object]